8-K/A: Whitehawk Therapeutics Completes Divestiture of Aadi Subsidiary, Reports Pro Forma Financials

Whitehawk Therapeutics finalizes the sale of its Aadi Subsidiary to KAKEN INVESTMENTS for $102.4 million and releases pro forma financial statements reflecting the transaction.

Summary

• Whitehawk Therapeutics, Inc. completed the sale of 100% of its Aadi Subsidiary, Inc. to KAKEN INVESTMENTS INC. on March 25, 2025.
• The sale was executed under a Stock Purchase Agreement dated December 19, 2024.
• Whitehawk received $102.4 million in cash proceeds, subject to purchase price adjustments.
• Stockholder approval for the divestiture was obtained on February 28, 2025.
• Pro forma financial statements, prepared in accordance with Article 11 of Regulation S-X, show the hypothetical impact of the divestiture on the company's financials as if it had occurred earlier.
• The pro forma balance sheet as of December 31, 2024, assumes the divestiture occurred on that date, resulting in total assets of $152.506 million.
• The pro forma statement of operations for the year ended December 31, 2024, reflects the transaction as if it occurred on January 1, 2024, resulting in a net loss of $25.233 million.
• The accounting adjustments include the sale of assets related to the FYARRO program and the receipt of cash proceeds.
• Management has chosen not to disclose synergy or dis-synergy adjustments, believing it would not enhance understanding of the pro forma effects.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The company completed a divestiture, which provides cash but also reduces future revenue potential. The pro forma financials show a net loss, but this is expected given the nature of the transaction.

Positives

• The company received $102.4 million in cash proceeds from the sale of Aadi Subsidiary, Inc.
• The divestiture allows Whitehawk Therapeutics to streamline its operations and focus on its remaining assets.

Negatives

• The pro forma statement of operations shows a net loss of $25.233 million for the year ended December 31, 2024, after giving effect to the divestiture.

Risks

• The pro forma financial information is not necessarily indicative of the actual financial position or future results of operations.
• Actual amounts could differ materially from the estimates presented in the pro forma statements.

Future Outlook

The pro forma financial information is presented for informational purposes only and is not intended to be indicative of the actual financial position or future results of operations.

Industry Context

The divestiture reflects a strategic decision by Whitehawk Therapeutics to focus on core assets and potentially streamline operations in a competitive pharmaceutical market.

Comparison to Industry Standards

• It is difficult to compare the results to industry standards without knowing the specific details of Aadi Subsidiary's operations and the rationale behind the divestiture.
• Divestitures are common in the pharmaceutical industry as companies seek to optimize their portfolios and focus on areas of strategic advantage.
• Comparable transactions would need to be analyzed to determine if the $102.4 million sale price is in line with industry norms for similar assets.

Stakeholder Impact

• Shareholders may be impacted by the change in the company's asset base and future revenue potential.
• Employees of Aadi Subsidiary, Inc. are now employees of KAKEN INVESTMENTS INC.
• The divestiture may impact the company's relationships with suppliers and customers related to the FYARRO program.

Key Dates

Keywords

Divestiture, Aadi Subsidiary, Whitehawk Therapeutics, KAKEN INVESTMENTS, Pro Forma Financials, Sale, FYARRO, Stock Purchase Agreement